- Home
- CMPX vs GNFT Comparison
CMPX vs GNFT Comparison
Compare CMPX & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- GNFT
- Stock Information
- Founded
- CMPX 2014
- GNFT 1999
- Country
- CMPX United States
- GNFT France
- Employees
- CMPX N/A
- GNFT N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPX Health Care
- GNFT Health Care
- Exchange
- CMPX Nasdaq
- GNFT Nasdaq
- Market Cap
- CMPX 214.6M
- GNFT 172.2M
- IPO Year
- CMPX N/A
- GNFT 2019
- Fundamental
- Price
- CMPX $2.60
- GNFT $3.47
- Analyst Decision
- CMPX Strong Buy
- GNFT Strong Buy
- Analyst Count
- CMPX 4
- GNFT 1
- Target Price
- CMPX $13.75
- GNFT $13.00
- AVG Volume (30 Days)
- CMPX 2.2M
- GNFT 6.9K
- Earning Date
- CMPX 11-12-2024
- GNFT 09-19-2024
- Dividend Yield
- CMPX N/A
- GNFT N/A
- EPS Growth
- CMPX N/A
- GNFT N/A
- EPS
- CMPX N/A
- GNFT 0.47
- Revenue
- CMPX $850,000.00
- GNFT $86,225,222.00
- Revenue This Year
- CMPX N/A
- GNFT $145.20
- Revenue Next Year
- CMPX $613.39
- GNFT N/A
- P/E Ratio
- CMPX N/A
- GNFT $7.23
- Revenue Growth
- CMPX N/A
- GNFT 175.45
- 52 Week Low
- CMPX $0.77
- GNFT $3.33
- 52 Week High
- CMPX $2.70
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- CMPX 76.97
- GNFT 31.89
- Support Level
- CMPX $1.43
- GNFT $3.35
- Resistance Level
- CMPX $2.70
- GNFT $3.57
- Average True Range (ATR)
- CMPX 0.29
- GNFT 0.11
- MACD
- CMPX 0.12
- GNFT 0.01
- Stochastic Oscillator
- CMPX 92.31
- GNFT 21.82
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.